JP2023507795A5 - - Google Patents

Info

Publication number
JP2023507795A5
JP2023507795A5 JP2022538201A JP2022538201A JP2023507795A5 JP 2023507795 A5 JP2023507795 A5 JP 2023507795A5 JP 2022538201 A JP2022538201 A JP 2022538201A JP 2022538201 A JP2022538201 A JP 2022538201A JP 2023507795 A5 JP2023507795 A5 JP 2023507795A5
Authority
JP
Japan
Prior art keywords
seq
approximately
variable region
chain variable
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507795A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/066151 external-priority patent/WO2021127525A1/en
Publication of JP2023507795A publication Critical patent/JP2023507795A/ja
Publication of JP2023507795A5 publication Critical patent/JP2023507795A5/ja
Priority to JP2025207453A priority Critical patent/JP2026048712A/ja
Pending legal-status Critical Current

Links

JP2022538201A 2019-12-20 2020-12-18 第XI/XIa因子抗体の医薬製剤および投薬レジメン Pending JP2023507795A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025207453A JP2026048712A (ja) 2019-12-20 2025-11-28 第XI/XIa因子抗体の医薬製剤および投薬レジメン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951887P 2019-12-20 2019-12-20
US62/951,887 2019-12-20
PCT/US2020/066151 WO2021127525A1 (en) 2019-12-20 2020-12-18 Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025207453A Division JP2026048712A (ja) 2019-12-20 2025-11-28 第XI/XIa因子抗体の医薬製剤および投薬レジメン

Publications (2)

Publication Number Publication Date
JP2023507795A JP2023507795A (ja) 2023-02-27
JP2023507795A5 true JP2023507795A5 (cg-RX-API-DMAC7.html) 2023-12-15

Family

ID=76478578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538201A Pending JP2023507795A (ja) 2019-12-20 2020-12-18 第XI/XIa因子抗体の医薬製剤および投薬レジメン
JP2025207453A Pending JP2026048712A (ja) 2019-12-20 2025-11-28 第XI/XIa因子抗体の医薬製剤および投薬レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025207453A Pending JP2026048712A (ja) 2019-12-20 2025-11-28 第XI/XIa因子抗体の医薬製剤および投薬レジメン

Country Status (9)

Country Link
US (1) US20230071973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076511A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023507795A (cg-RX-API-DMAC7.html)
KR (1) KR20220119090A (cg-RX-API-DMAC7.html)
CN (1) CN115003325A (cg-RX-API-DMAC7.html)
BR (1) BR112022012064A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161118A1 (cg-RX-API-DMAC7.html)
IL (1) IL293367A (cg-RX-API-DMAC7.html)
WO (1) WO2021127525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
WO2023092062A1 (en) * 2021-11-18 2023-05-25 Anthos Therapeutics, Inc. Dosing regimens of factor xi/xia antibodies
EP4461749A4 (en) * 2022-01-05 2025-03-26 Shanghai Mabgen Biotech Ltd. Pharmaceutical composition containing anti-FXI/FXIA antibodies and use thereof
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子xi/因子xia抗體之組合療法
DE102022116219A1 (de) * 2022-06-29 2024-01-04 St. Jude Medical, Cardiology Division, Inc. Kandidatenscreening für eine Zieltherapie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738261A (en) * 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
WO2008039761A2 (en) * 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
JOP20160131B1 (ar) * 2015-06-26 2022-03-14 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
KR102616666B1 (ko) * 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
CN118320078A (zh) * 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
PT3570882T (pt) * 2017-01-19 2022-01-11 Bayer Pharma AG Nova formulação estável para anticorpos fxia
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2023092062A1 (en) * 2021-11-18 2023-05-25 Anthos Therapeutics, Inc. Dosing regimens of factor xi/xia antibodies

Similar Documents

Publication Publication Date Title
US20250074985A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
US9220776B2 (en) Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
JP2021046431A (ja) 血管性眼疾患を処置するための方法および製剤
TWI894144B (zh) 藉由投予il-33拮抗劑治療或預防哮喘之方法
KR20200034739A (ko) 고농도 항-c5 항체 제형
BR112021008778A2 (pt) Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn
WO2020259605A1 (zh) 包含抗cd47/pd-l1双特异性抗体的制剂及其制备方法和用途
BR112021010789A2 (pt) Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar
NO20170737A1 (no) Anvendelse av anti-CD3 antistoff for fremstilling av et medikament mot aterosklerose, samt et anti-CD3 antistoff
JP2026048712A (ja) 第XI/XIa因子抗体の医薬製剤および投薬レジメン
TW202045537A (zh) 化膿性汗腺炎的治療
CN113194821A (zh) 逆转替卡格雷活性的方法
TW202128133A (zh) 重組全人源抗tigit單株抗體製劑及其製備方法和用途
WO2025130748A1 (zh) 一种抗凝血因子XI/XIa抗体制剂
KR20250079929A (ko) 항-FcRN 항체를 이용한 그레이브스병의 치료 방법
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
RU2745814C1 (ru) Водная фармацевтическая композиция левилимаба и ее применение
CN116172947A (zh) 一种含特异性结合vegf和ang2的双特异性抗体的药物组合物
CN115531531A (zh) 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途
TW202206457A (zh) 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
CN116688115B (zh) 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途
BR112021004900A2 (pt) anticorpos de quimiocina pan-elr+ cxc para o tratamento de hidradenitis suppurativa
HK40102408B (en) Pharmaceutical composition containing anti-lag-3 antibody and application thereof
HK40102408A (en) Pharmaceutical composition containing anti-lag-3 antibody and application thereof
JP2019505516A (ja) インターロイキン−17(il−17)アンタゴニストを使用してざ瘡を治療する方法